Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …
treatment in most cases. However, a small subset of pituitary tumours does not respond to …
Epidemiologic and molecular prognostic review of glioblastoma
Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous
system malignancy with a median survival of 15 months. The average incidence rate of GBM …
system malignancy with a median survival of 15 months. The average incidence rate of GBM …
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter …
U Herrlinger, T Tzaridis, F Mack, JP Steinbach… - The lancet, 2019 - thelancet.com
Background There is an urgent need for more effective therapies for glioblastoma. Data from
a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus …
a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus …
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 …
M Weller, N Butowski, DD Tran, LD Recht, M Lim… - The lancet …, 2017 - thelancet.com
Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR
deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole …
deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole …
Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma
Background Standard therapy for newly diagnosed glioblastoma is radiotherapy plus
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab …
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab …
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year …
Background In 2004, a randomised phase III trial by the European Organisation for
Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada …
Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada …
Primary brain tumours in adults
Important advances have been made in the understanding and management of adult
gliomas and primary CNS lymphomas—the two most common primary brain tumours …
gliomas and primary CNS lymphomas—the two most common primary brain tumours …
The many facets of therapy resistance and tumor recurrence in glioblastoma
Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using
chemo-and radio-therapy modestly increases the overall survival of patients; however …
chemo-and radio-therapy modestly increases the overall survival of patients; however …
Current concepts and management of glioblastoma
Glioblastoma is the most common malignant primary brain tumor in adults. Its often rapid
clinical course, with many medical and psychosocial challenges, requires a multidisciplinary …
clinical course, with many medical and psychosocial challenges, requires a multidisciplinary …
Glioblastoma multiforme: a review of where we have been and where we are going
Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest
challenges in the management of cancer patients worldwide, despite notable recent …
challenges in the management of cancer patients worldwide, despite notable recent …